, /PRNewswire/ -- Modern Meadow, a creator of innovative, environmentally-friendly biomaterials whose mission is to enable the world to transition to sustainable materials, today announced that it has shifted its strategic direction to focus solely on its biomaterials business. The company is pleased to announce the sale of its beauty and biomedical divisions to HTL Biotechnology, a French biotech company responsible for the development and biomanufacturing of pharmaceutical-grade polymers. This divestiture signals a strategic commitment to expanding innovations in biology and materials science to accelerate progress across the industry, and enable companies to bring high-quality, sustainable products to market worldwide.
, PhD, has been named as the President and COO and will lead the company's efforts to prioritize and accelerate the growth of its biomaterials business. Prior to working at Modern Meadow, Dr. Williamson spent over a decade at DuPont building and leading a variety of key technical and operations initiatives.
"The collaboration between design, biology, and material science will lead to real-world solutions that make a meaningful difference for people and the planet," said Dr. Williamson. "Our decision to focus on our bio-materials business will drive both our research and commercial efforts in this sector and bring next-gen products to industries such as apparel, footwear, outdoor, and automotive.
HTL is the ideal acquirer for our Beauty and BioMed business, c.